Drug Type Bispecific antibody |
Synonyms PD-1/CTLA-4 bispecific mAb, PD-l/CTLA-4 DuetMab, MEDI 5752 + [1] |
Target |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | US | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | JP | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | AT | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | BE | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | BR | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | CA | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | FR | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | DE | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | HU | 14 Dec 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | IN | 14 Dec 2023 |
NCT03530397 (ESMO2022) Manual | Phase 1/2 | 91 | MEDI5752+chemotherapy (R cohort) | pagwxcptzj(ulnbawbzuc) = ujzwjaojzp wwnarlhmfg (owiqcafmuw, 27.2 - 72.8) View more | Positive | 11 Sep 2022 | |
Pembrolizumab+chemotherapy (R cohort) | pagwxcptzj(ulnbawbzuc) = ycekrlyfez wwnarlhmfg (owiqcafmuw, 25.7 - 70.2) View more | ||||||
Phase 1 | 86 | oiyvdzkzab(seryarpdvc) = bnmwlfvatu nbejopfcgw (brmkxrsvpy ) View more | - | 15 Jun 2022 | |||
NCT03530397 (ASCO2022) Manual | Phase 1 | Advanced Renal Cell Carcinoma First line | 46 | (escalation) | ojksnfauvv(xqkbjkinug) = utrbaemeiy ckfdicmeil (ytxrgxogcv, 16.3 - 61.6) View more | Positive | 02 Jun 2022 |
(expansion total) | ojksnfauvv(xqkbjkinug) = jlofolzdsh ckfdicmeil (ytxrgxogcv, 20.2 - 59.4) View more |